SPY001 — Clinical data readout
in 2026
Part A: Open-label assessment of the safety and preliminary efficacy of a single dose level of each investigational monotherapy, with induction data expected in 2026.Source filing
SYRE biotech catalysts & pipeline
SPYRE THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
SPY072 — Topline data
Q4 2026
Topline data for SPY072 in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) on track for Q4 2026 and for SPY072 in combination with IL17-A/F in hidradenitis suppurativa (HS) in late 2027 or early 2028Source filing
SPY072 — Clinical data readout
4Q 2026
All indications are expected to readout in 4Q 2026.Source filing
monotherapies and combinations — Clinical data readout
2027
Part B: Randomized and placebo-controlled assessment of the safety and efficacy of monotherapies and combinations, designed to provide dose-ranging data on monotherapies, proof-of-concept, and contribution of components for combinations, with induction data expected in 2027.Source filing
SPY001, SPY002, SPY003, SPY120, SPY130, SPY230 — Topline data
2027
SKYLINE Part B evaluating pairwise combinations of these components is enrolling with topline induction data expected in 2027Source filing
SPY002 (anti-TL1A) — Clinical data readout
2027
We have begun enrolling these combinations globally and look forward to unveiling proof-of-concept data next year.Source filing
SPY072 + IL-17A/F — Clinical data readout
Sep 2027–Apr 2028
SKYLIGHT HS SPY072 + IL-17A/F Late 2027 or early 2028Source filing
SPY072 + IL17-A/F — Topline data
Sep 2027–Apr 2028
Topline data for SPY072 in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) on track for Q4 2026 and for SPY072 in combination with IL17-A/F in hidradenitis suppurativa (HS) in late 2027 or early 2028Source filing
SPY003 — Topline data
Sep 2026
Enrollment for Part A has completed, with SPY001 and SPY002 Part A topline induction data announced in Q2 2026, and topline data expected for SPY003 in September 2026.Source filing